Approximately every three minutes, a person in the United States is diagnosed with a blood cancer; every nine minutes, someone dies from it.

The Leukemia & Lymphoma Society (LLS) exists to fund research, find cures and ensure access to treatments for all blood cancer patients.

Since 1949, LLS has been on the forefront of blood cancer advances such as chemotherapies and stem cell transplantation, and has led the way to the development of targeted therapies and immunotherapies that are saving thousands of lives. Sustained research investments are fueling an explosion of innovative science and clinical successes.

To date, LLS has invested more than $1 billion in research to advance the potential for cures. LLS research grants have funded many of today’s most promising advances.

Currently, the organization is supporting approximately 300 active research projects that explore different avenues of new and leading-edge research.

One of those projects is aimed at the most daunting challenge in blood cancer: acute myeloid leukemia (AML), one of the most common types of leukemia in adults. In October 2016, LLS launched a paradigm-shifting clinical trial to test investigational targeted therapies against multiple subtypes of AML at multiple research institutions. With today’s chemotherapies, the same that have been used for more than 40 years, only one in four AML patients survives five years beyond diagnosis, but LLS hopes to change that. Through this unprecedented offensive known as the “Beat AML Master Trial,” up to 500 adult patients will be enrolled over the course of 3-5 years with the hopes of bringing new treatments and new hope.

LLS is the voice for all blood cancer patients and is working to ensure that each and every one of them has access to the most effective help possible. LLS has taken an unapologetically patients first position on the cost of cancer care, and this past May, organized a panel discussion featuring some of the nation’s leading experts on blood cancers and healthcare policy to discuss the ever-increasing cost barriers that patients and their families face to access high-quality care. The panel examined the multiple components that constitute the economic burden of cancer care, which goes beyond direct medical costs to include the impact on a patient’s employment, time spent traveling to receive necessary therapies as well as taking care of loved ones during a course of treatment. The assembled experts then stressed the need to discuss the cost of cancer care in terms of value for patients. Panelists also highlighted the need for transparency throughout the healthcare ecosystem, which applies to the prices of specialty drugs, as well as the importance for providers to have conversations about cost with their patients at the same time that they discuss treatment options.

Prev